Castle Biosciences Rallies 64.7% with Zacks Strong Buy Rating, Loss Estimates Trimmed
Castle Biosciences holds a Zacks Rank #1 with its shares rallying 64.7% over the past six months and 16% year to date, outpacing the biotech sector. Analysts have narrowed 2025 loss-per-share forecasts from $0.34 to $0.29 and trimmed 2026 estimates from $1.11 to $0.96.
1. Zacks Rank and Stock Performance
Castle Biosciences carries a Zacks Rank #1 (Strong Buy) rating, reflecting bullish analyst sentiment. Its shares have surged 64.7% over the past six months and climbed 16% year to date, significantly outpacing the broader biotech industry.
2. Earnings Surprise Track Record
The company has beaten earnings estimates in three of the trailing four quarters, delivering an average surprise of 66.11%. These consistent upside surprises have underpinned investor confidence and contributed to the sharp stock gain.
3. Analyst Estimate Revisions
Over the past 60 days, consensus loss-per-share estimates for 2025 have been revised down from $0.34 to $0.29, while 2026 estimates have been trimmed from $1.11 to $0.96. The revisions reflect improving operational efficiency and confidence in the company’s near-term financial trajectory.